Tags

Type your tag names separated by a space and hit enter

Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.
J Nucl Med. 2015 Apr; 56(4):560-6.JN

Abstract

In this article, we describe an image analysis strategy with improved power for tracking longitudinal amyloid-β (Aβ) PET changes and evaluating Aβ-modifying treatments.

METHODS

Our aims were to compare the power of template-based cerebellar, pontine, and cerebral white matter reference regions to track 24-mo florbetapir standardized uptake value (SUV) ratio (SUVR) changes; to relate those changes to 24-mo clinical declines; and to evaluate Aβ-modifying treatments in Aβ-positive (Aβ+) and Aβ-negative (Aβ-) patients with probable Alzheimer dementia (pAD), in patients with mild cognitive impairment (MCI), in cognitively normal controls (NCs), and in cognitively normal apolipoprotein E4 (APOE4) carriers and noncarriers. We used baseline and follow-up (∼24 mo) florbetapir PET scans from 332 Aβ+ and Aβ- subjects participating in the multicenter Alzheimer's Disease Neuroimaging Initiative. Each of the proposed analyses included 31 pAD patients, 187 MCI patients, and 114 NCs. Cerebral-to-white matter, cerebellar, and pontine SUVRs were characterized in terms of their longitudinal variability; their power to track longitudinal fibrillar Aβ increases in Aβ+ and Aβ- subgroups and cognitively normal APOE4 carriers and noncarriers; the sample sizes needed to detect attenuated accumulation of or clearance of fibrillar Aβ accumulation in randomized clinical trials; and their ability to relate 24-mo fibrillar Aβ increases to clinical declines.

RESULTS

As predicted, cerebral-to-white matter SUVR changes were significantly less variable and had significantly greater power to detect 24-mo fibrillar Aβ increases and evaluate Aβ-modifying treatment effects in Aβ+ pAD, MCI, and NC subjects and cognitively normal APOE4 carriers. They were also distinguished by the ability to detect significant associations between 24-mo Aβ increases and clinical declines.

CONCLUSION

A cerebral white matter reference region may improve the power to track longitudinal fibrillar Aβ increases, to characterize their relationship to longitudinal clinical declines, and to evaluate Aβ-modifying treatments in randomized clinical trials.

Authors+Show Affiliations

Banner Alzheimer's Institute, Phoenix, Arizona Department of Mathematics and Statistics, Arizona State University, Tempe, Arizona Department of Neurology, College of Medicine, University of Arizona, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona kewei.chen@bannerhealth.com.Banner Alzheimer's Institute, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona.Banner Alzheimer's Institute, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona.Banner Alzheimer's Institute, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona.Banner Alzheimer's Institute, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona.Banner Alzheimer's Institute, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona.Banner Alzheimer's Institute, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona.Banner Alzheimer's Institute, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona.Banner Alzheimer's Institute, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona.Banner Alzheimer's Institute, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona.Banner Alzheimer's Institute, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona.Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, Michigan.Arizona Alzheimer's Consortium, Phoenix, Arizona Eli Lilly and Company, Indianapolis, Indiana Department of Neuroscience, University of California-San Diego, San Diego, California.Arizona Alzheimer's Consortium, Phoenix, Arizona Mayo Clinic, Scottsdale, Arizona.School of Public Health and Helen Wills Neuroscience Institute, University of California-Berkeley, Berkeley, California.School of Public Health and Helen Wills Neuroscience Institute, University of California-Berkeley, Berkeley, California.Department of Radiology, University of California-San Francisco, San Francisco, California Department of Medicine, University of California-San Francisco, San Francisco, California Department of Psychiatry, University of California-San Francisco, San Francisco, California.Banner Alzheimer's Institute, Phoenix, Arizona Arizona Alzheimer's Consortium, Phoenix, Arizona Division of Neurogenomics, Translational Genomics Research Institute, Phoenix, Arizona; and Department of Psychiatry, University of Arizona, Tucson, Arizona.No affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

25745091

Citation

Chen, Kewei, et al. "Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-modifying Treatments With a Cerebral White Matter Reference Region." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 56, no. 4, 2015, pp. 560-6.
Chen K, Roontiva A, Thiyyagura P, et al. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56(4):560-6.
Chen, K., Roontiva, A., Thiyyagura, P., Lee, W., Liu, X., Ayutyanont, N., Protas, H., Luo, J. L., Bauer, R., Reschke, C., Bandy, D., Koeppe, R. A., Fleisher, A. S., Caselli, R. J., Landau, S., Jagust, W. J., Weiner, M. W., & Reiman, E. M. (2015). Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 56(4), 560-6. https://doi.org/10.2967/jnumed.114.149732
Chen K, et al. Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-modifying Treatments With a Cerebral White Matter Reference Region. J Nucl Med. 2015;56(4):560-6. PubMed PMID: 25745091.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. AU - Chen,Kewei, AU - Roontiva,Auttawut, AU - Thiyyagura,Pradeep, AU - Lee,Wendy, AU - Liu,Xiaofen, AU - Ayutyanont,Napatkamon, AU - Protas,Hillary, AU - Luo,Ji Luo, AU - Bauer,Robert, AU - Reschke,Cole, AU - Bandy,Daniel, AU - Koeppe,Robert A, AU - Fleisher,Adam S, AU - Caselli,Richard J, AU - Landau,Susan, AU - Jagust,William J, AU - Weiner,Michael W, AU - Reiman,Eric M, AU - ,, Y1 - 2015/03/05/ PY - 2014/10/22/received PY - 2014/12/26/accepted PY - 2015/3/7/entrez PY - 2015/3/7/pubmed PY - 2015/6/16/medline KW - Alzheimer disease KW - biomarkers KW - clinical trial sample size KW - florbetapir PET KW - image analysis KW - statistical power SP - 560 EP - 6 JF - Journal of nuclear medicine : official publication, Society of Nuclear Medicine JO - J. Nucl. Med. VL - 56 IS - 4 N2 - UNLABELLED: In this article, we describe an image analysis strategy with improved power for tracking longitudinal amyloid-β (Aβ) PET changes and evaluating Aβ-modifying treatments. METHODS: Our aims were to compare the power of template-based cerebellar, pontine, and cerebral white matter reference regions to track 24-mo florbetapir standardized uptake value (SUV) ratio (SUVR) changes; to relate those changes to 24-mo clinical declines; and to evaluate Aβ-modifying treatments in Aβ-positive (Aβ+) and Aβ-negative (Aβ-) patients with probable Alzheimer dementia (pAD), in patients with mild cognitive impairment (MCI), in cognitively normal controls (NCs), and in cognitively normal apolipoprotein E4 (APOE4) carriers and noncarriers. We used baseline and follow-up (∼24 mo) florbetapir PET scans from 332 Aβ+ and Aβ- subjects participating in the multicenter Alzheimer's Disease Neuroimaging Initiative. Each of the proposed analyses included 31 pAD patients, 187 MCI patients, and 114 NCs. Cerebral-to-white matter, cerebellar, and pontine SUVRs were characterized in terms of their longitudinal variability; their power to track longitudinal fibrillar Aβ increases in Aβ+ and Aβ- subgroups and cognitively normal APOE4 carriers and noncarriers; the sample sizes needed to detect attenuated accumulation of or clearance of fibrillar Aβ accumulation in randomized clinical trials; and their ability to relate 24-mo fibrillar Aβ increases to clinical declines. RESULTS: As predicted, cerebral-to-white matter SUVR changes were significantly less variable and had significantly greater power to detect 24-mo fibrillar Aβ increases and evaluate Aβ-modifying treatment effects in Aβ+ pAD, MCI, and NC subjects and cognitively normal APOE4 carriers. They were also distinguished by the ability to detect significant associations between 24-mo Aβ increases and clinical declines. CONCLUSION: A cerebral white matter reference region may improve the power to track longitudinal fibrillar Aβ increases, to characterize their relationship to longitudinal clinical declines, and to evaluate Aβ-modifying treatments in randomized clinical trials. SN - 1535-5667 UR - https://www.unboundmedicine.com/medline/citation/25745091/Improved_power_for_characterizing_longitudinal_amyloid_β_PET_changes_and_evaluating_amyloid_modifying_treatments_with_a_cerebral_white_matter_reference_region_ L2 - http://jnm.snmjournals.org/cgi/pmidlookup?view=long&pmid=25745091 DB - PRIME DP - Unbound Medicine ER -